The Conversation (0)
Oncolytics Biotech announced its financial results for the third quarter of 2017.
Oncolytics Biotech (TSX:ONC; OTCQX:ONCYF) announced its financial results for the third quarter of 2017.
As quoted in the press release:
“Towards the end of the third quarter we made a very important announcement regarding feedback from the FDA following our End-of-Phase 2 meeting. The favorable meeting resulted in the support of our proposed target patient population of hormone receptor positive, HER2 receptor negative metastatic breast cancer patients for our registration study,” said Dr. Matt Coffey, President and CEO of Oncolytics Biotech. “With this support and guidance outlining a single, four hundred patient study, we have prepared to file for breakthrough designation which we expect to do very soon, prepared for communications with the European regulators, conducted preliminary preparations to file for a special protocol assessment, or SPA, and advanced our business development activities. We expect to be able to announce the results of these filings and communications with the European regulators over the next several months as we continue to prepare the company to relist its shares on NASDAQ in 2018.”
Click here to read the full press release.
Source: www.newswire.ca